Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.
Front Oncol
January 2025
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.
Case Description: This report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, ).
Case report: Clinical workflow considerations for treating soft-tissue sarcoma on a 1.5-T MR-Linac.
Tech Innov Patient Support Radiat Oncol
March 2025
MD Anderson Cancer Center at Cooper, 2 Cooper Plaza, Camden, NJ 08103, USA.
We present specific issues that arose when using a 1.5-Tesla MR-Linac to treat a series of 4 soft-tissue sarcoma (STS) patients. These issues arose from the combination of typical STS attributes (long, off-axis target) and MR-Linac design-specific limitations on field size and patient positioning.
View Article and Find Full Text PDFDifficulties in the diagnosis and treatment of axillary malignant triton tumors: A case report.
Oncol Lett
March 2025
Department of Oncology, The Liuzhou Worker's Hospital, Liuzhou, Guangxi Zhuang Autonomous Region 545005, P.R. China.
Malignant triton tumor (MTT), a subtype of malignant peripheral nerve sheath tumor, is a rare soft-tissue sarcoma with a difficult diagnosis and poor prognosis. The course of MTT progression is rapid and the degree of malignancy is high. Patients with MTT can be treated with postoperative adjuvant radiotherapy and chemotherapy; however, treatment results are still poor.
View Article and Find Full Text PDFHealth networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).
ESMO Open
January 2025
Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Health networking is in principle a formidable instrument to address many challenges posed by cancer, one of the two most common and most lethal non-communicable chronic diseases. The European Union (EU)'s Beating Cancer Plan foresaw the addition of new health networks to the four already existing European Reference Networks on rare cancers: the Network of Comprehensive Cancer Centres and several networks of expertise (NoEs), which will be shortly deployed on items as complex and poor-prognosis cancers, palliative care, survivorship, personalised primary and secondary prevention, omic technologies, hi-tech medical resources, and cancers in adolescents and young adults. The community of experts of the EU Joint Action, due to build such NoEs, has drafted this 'green paper', incorporating 13 open questions, in an effort to foster discussion on some open questions about health networking on cancer in the EU.
View Article and Find Full Text PDFEmerging treatments for sarcoma: from 2024 onward.
Expert Opin Emerg Drugs
January 2025
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Introduction: Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized disease, surgery and radiotherapy remain the cornerstone treatments. However, systemic options for advanced stages are limited, with an overall survival of approximately 20 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!